-
Characterizing the Shared Genetic Underpinnings of Schizophrenia and Cardiovascular Disease Risk Factors Am. J. Psychiatry (IF 17.7) Pub Date : 2023-09-27 Linn Rødevand, Zillur Rahman, Guy F.L. Hindley, Olav B. Smeland, Oleksandr Frei, Tahir Filiz Tekin, Gleda Kutrolli, Shahram Bahrami, Eva Z. Hoseth, Alexey Shadrin, Aihua Lin, Srdjan Djurovic, Anders M. Dale, Nils Eiel Steen, Ole A. Andreassen
Objective: Schizophrenia is associated with increased risk of cardiovascular disease (CVD), although there is variation in risk among individuals. There are indications of shared genetic etiology between schizophrenia and CVD, but the nature of the overlap remains unclear. The aim of this study was to fill this gap in knowledge. Methods: Overlapping genetic architectures between schizophrenia and CVD
-
Balancing complexity and accessibility with the Psymatik Treatment Optimizer Lancet Psychiatry (IF 64.3) Pub Date : 2023-09-26 Laila Asmal, Tamara Kredo
Abstract not available
-
Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development Lancet Psychiatry (IF 64.3) Pub Date : 2023-09-26 Toby Pillinger, Oliver D Howes, Christoph U Correll, Stefan Leucht, Maximilian Huhn, Johannes Schneider-Thoma, Fiona Gaughran, Sameer Jauhar, Philip K McGuire, David M Taylor, Allan H Young, Robert A McCutcheon
Background Side-effects of psychiatric medication impair quality of life and functioning. Furthermore, they contribute to morbidity, mortality, stigma, and poor treatment concordance resulting in relapse of psychiatric illness. Guidelines recommend discussing side-effects with patients when making treatment decisions, but a synthesis of antidepressant and antipsychotic side-effects to guide this process
-
International consensus on patient-centred outcomes in eating disorders Lancet Psychiatry (IF 64.3) Pub Date : 2023-09-25 Amelia Austin, Umanga De Silva, Christiana Ilesanmi, Theerawich Likitabhorn, Isabel Miller, Maria da Luz Sousa Fialho, S Bryn Austin, Belinda Caldwell, Chu Shan Elaine Chew, Sook Ning Chua, Suzanne Dooley-Hash, James Downs, Carine El Khazen Hadati, Beate Herpertz-Dahlmann, Jillian Lampert, Yael Latzer, Paulo P P Machado, Sarah Maguire, Madeeha Malik, Carolina Meira Moser, Tracy K Richmond
The effectiveness of mental health care can be improved through coordinated and wide-scale outcome measurement. The International Consortium for Health Outcomes Measurement has produced collaborative sets of outcome measures for various mental health conditions, but no universal guideline exists for eating disorders. This Position Paper presents a set of outcomes and measures for eating disorders as
-
A brain-wide risk score for psychiatric disorder evaluated in a large adolescent population reveals increased divergence among higher-risk groups relative to controls Biol. Psychiatry (IF 10.6) Pub Date : 2023-09-26 Weizheng Yan, Godfrey D. Pearlson, Zening Fu, Xinhui Li, Armin Iraji, Jiayu Chen, Jing Sui, Nora D. Volkow, Vince D. Calhoun
Background Accurate psychiatric risk assessment requires biomarkers that are both stable and adaptable to development. Functional network connectivity (FNC), which steadily reconfigures over time, potentially contains abundant information to assess psychiatric risks. However, the absence of suitable analytical methodologies has constrained this area of investigation. Methods We investigated brain-wide
-
Brain Functional Connectome Defines a Transdiagnostic Dimension Shared by Cognitive Function and Psychopathology in Preadolescents Biol. Psychiatry (IF 10.6) Pub Date : 2023-09-26 Xiang Xiao, Christopher Hammond, Betty Jo Salmeron, Danni Wang, Hong Gu, Tianye Zhai, Hieu Nguyen, Hanbing Lu, Thomas J. Ross, Yihong Yang
Background Cognitive function and general psychopathology are two important classes of human behavior dimensions, individually relate to mental disorders across diagnostic categories. However, whether the two transdiagnostic dimensions link to common or distinct brain networks that convey resilience or risk for the development of psychiatric disorders remains unclear. Method The current study is a
-
Tau: a biomarker of Huntington’s disease Mol. Psychiatry (IF 11.0) Pub Date : 2023-09-25 Eva Lepinay, Francesca Cicchetti
-
Blunted glucocorticoid responsiveness to stress causes behavioral and biological alterations that lead to posttraumatic stress disorder vulnerability Biol. Psychiatry (IF 10.6) Pub Date : 2023-09-23 Silvia Monari, Isabelle Guillot de Suduiraut, Jocelyn Grosse, Olivia Zanoletti, Sophie E. Walker, Michel Mesquita, Tobias C. Wood, Diana Cash, Simone Astori, Carmen Sandi
BACKGROUND Understanding why only a subset of trauma-exposed individuals develop posttraumatic stress disorder (PTSD) is critical for advancing clinical strategies. A few behavioral (deficits in fear extinction) and biological (blunted glucocorticoid levels, small hippocampal size, and rapid-eye movement sleep (REMS) disturbances) traits have been identified as potential vulnerability factors. However
-
Disentangling the individual-shared and individual-specific subspace of altered brain functional connectivity in autism spectrum disorder Biol. Psychiatry (IF 10.6) Pub Date : 2023-09-22 Xiaolong Shan, Lucina Q. Uddin, Rui Ma, Pengfei Xu, Jinming Xiao, Lei Li, Xinyue Huang, Yu Feng, Changchun He, Huafu Chen, Xujun Duan
Background Despite considerable effort towards understanding the neural basis of autism spectrum disorder (ASD) using case-control analyses of resting-state functional magnetic resonance imaging data, findings are often not reproducible, largely due to biological and clinical heterogeneity among individuals with ASD. Thus, exploring the individual-shared and individual-specific altered functional connectivity
-
Loneliness and depression: bidirectional mendelian randomization analyses using data from three large genome-wide association studies Mol. Psychiatry (IF 11.0) Pub Date : 2023-09-21 David A. Sbarra, Ferris A. Ramadan, Karmel W. Choi, Jorien L. Treur, Daniel F. Levey, Robyn E. Wootton, Murray B. Stein, Joel Gelernter, Yann C. Klimentidis
-
Automated virtual reality cognitive therapy versus virtual reality mental relaxation therapy for the treatment of persistent persecutory delusions in patients with psychosis (THRIVE): a parallel-group, single-blind, randomised controlled trial in England with mediation analyses Lancet Psychiatry (IF 64.3) Pub Date : 2023-09-21 Daniel Freeman, Rachel Lister, Felicity Waite, Ushma Galal, Ly-Mee Yu, Sinéad Lambe, Ariane Beckley, Emily Bold, Lucy Jenner, Rowan Diamond, Miriam Kirkham, Eve Twivy, Chiara Causier, Lydia Carr, Simone Saidel, Rebecca Day, Alejandro Beacco, Aitor Rovira, Annabel Ivins, Ryan Nah, Laina Rosebrock
Background Persecutory delusions are a major psychiatric problem that often do not respond sufficiently to standard pharmacological or psychological treatments. We developed a new brief automated virtual reality (VR) cognitive treatment that has the potential to be used easily in clinical services. We aimed to compare VR cognitive therapy with an alternative VR therapy (mental relaxation), with an
-
Closed-loop stimulation Biol. Psychiatry (IF 10.6) Pub Date : 2023-09-22 Christoph Zrenner, Ulf Ziemann
In the same way that beauty lies in the eye of the beholder, what a stimulus does to the brain is determined not simply by the nature of the stimulus, but by the nature of the brain receiving the stimulus, at that instant of time. Therapeutic brain stimulation, over the past decades, typically applied open-loop fixed protocols and has largely ignored this principle. Only recent neuro-technological
-
Target engagement and brain state dependence of transcranial magnetic stimulation: implications for clinical practice Biol. Psychiatry (IF 10.6) Pub Date : 2023-09-21 Alexander T. Sack, Jasmina Paneva, Tara Küthe, Eva Dijkstra, Lauren Zwienenberg, Martijn Arns, Teresa Schuhmann
Transcranial Magnetic Stimulation (TMS) is capable of noninvasively inducing lasting neuroplastic changes when applied repetitively across multiple treatment sessions. In recent years, repetitive TMS has developed into an established evidence-based treatment for various neuropsychiatric disorders such as depression. Despite significant advancements in our understanding of the mechanisms of action of
-
Evaluating Robustness of Brain Stimulation Biomarkers for depression: A Systematic Review of MRI and EEG Studies Biol. Psychiatry (IF 10.6) Pub Date : 2023-09-19 Debby Klooster, Helena Voetterl, Chris Baeken, Martijn Arns
Non-invasive brain stimulation (NIBS) treatments have gained considerable attention as a potential therapeutic intervention for psychiatric disorders. The identification of reliable biomarkers for predicting clinical response to NIBS has been a major focus of research in recent years. Neuroimaging techniques, such as electroencephalography (EEG) and (functional) magnetic resonance imaging (fMRI), have
-
GRIN2A (NR2A): a gene contributing to glutamatergic involvement in schizophrenia Mol. Psychiatry (IF 11.0) Pub Date : 2023-09-22 Paul J. Harrison, David M. Bannerman
-
Covariation of preadult environmental exposures, adult brain imaging phenotypes, and adult personality traits Mol. Psychiatry (IF 11.0) Pub Date : 2023-09-22 Kaizhong Xue, Bo Gao, Feng Chen, Meiyun Wang, Jingliang Cheng, Bing Zhang, Wenzhen Zhu, Shijun Qiu, Zuojun Geng, Xiaochu Zhang, Guangbin Cui, Yongqiang Yu, Quan Zhang, Weihua Liao, Hui Zhang, Xiaojun Xu, Tong Han, Wen Qin, Feng Liu, Meng Liang, Lining Guo, Qiang Xu, Jiayuan Xu, Jilian Fu, Peng Zhang, Wei Li, Dapeng Shi, Caihong Wang, Su Lui, Zhihan Yan, Jing Zhang, Jiance Li, Dawei Wang, Junfang Xian
-
Long non-coding RNA SNHG8 drives stress granule formation in tauopathies Mol. Psychiatry (IF 11.0) Pub Date : 2023-09-21 Reshma Bhagat, Miguel A. Minaya, Arun Renganathan, Muneshwar Mehra, Jacob Marsh, Rita Martinez, Abdallah M. Eteleeb, Alissa L. Nana, Salvatore Spina, William W. Seeley, Lea T. Grinberg, Celeste M. Karch
-
Strong associations of telomere length and mitochondrial copy number with suicidality and abuse history in adolescent depressed individuals Mol. Psychiatry (IF 11.0) Pub Date : 2023-09-21 Shinichiro Ochi, Bhaskar Roy, Kevin Prall, Richard C. Shelton, Yogesh Dwivedi
-
Tau suppresses microtubule-regulated pancreatic insulin secretion Mol. Psychiatry (IF 11.0) Pub Date : 2023-09-21 Salvatore P. Mangiafico, Qing-Zhang Tuo, Xiao-Lan Li, Yu Liu, Christian Haralambous, Xu-Long Ding, Scott Ayton, Qing Wang, D. Ross Laybutt, Jeng Yie Chan, Xiang Zhang, Cameron Kos, Helen E. Thomas, Thomas Loudovaris, Chieh-Hsin Yang, Christos N. Joannides, Benjamin J. Lamont, Lunzhi Dai, Hai-Huai He, Biao Dong, Sofianos Andrikopoulos, Ashley I. Bush, Peng Lei
-
The PFC-LH-VTA pathway contributes to social deficits in IRSp53-mutant mice Mol. Psychiatry (IF 11.0) Pub Date : 2023-09-20 Young Woo Noh, Yangsik Kim, Soowon Lee, Yeonghyeon Kim, Jae Jin Shin, Hyojin Kang, Il Hwan Kim, Eunjoon Kim
-
Virtual reality treatments for patients with persecutory delusions: new developments and new questions Lancet Psychiatry (IF 64.3) Pub Date : 2023-09-21 Stephanie Mehl
Abstract not available
-
Complex PTSD as mediator of psychosis after childhood trauma Lancet Psychiatry (IF 64.3) Pub Date : 2023-09-20 Nynke A Groenewold
Abstract not available
-
Decoding anxiety–impulsivity subtypes in preadolescent internalising disorders: findings from the Adolescent Brain Cognitive Development study Br. J. Psychiatry (IF 10.5) Pub Date : 2023-09-21 Huaxin Fan, Zhaowen Liu, Xinran Wu, Gechang Yu, Xinrui Gu, Nanyu Kuang, Kai Zhang, Yu Liu, Tianye Jia, Barbara J. Sahakian, Trevor W. Robbins, Gunter Schumann, Wei Cheng, Jianfeng Feng, Benjamin Becker, Jie Zhang
Background Internalising disorders are highly prevalent emotional dysregulations during preadolescence but clinical decision-making is hampered by high heterogeneity. During this period impulsivity represents a major risk factor for psychopathological trajectories and may act on this heterogeneity given the controversial anxiety–impulsivity relationships. However, how impulsivity contributes to the
-
Impact of the COVID-19 pandemic on self-harm and self-harm/suicide ideation: population-wide data linkage study and time series analysis Br. J. Psychiatry (IF 10.5) Pub Date : 2023-09-21 Euan Neil Paterson, Lisa Kent, Dermot O'Reilly, Denise O'Hagan, Siobhan M. O'Neill, Aideen Maguire
Background The COVID-19 pandemic and associated lockdowns were predicted to have a major impact on suicidal behaviour, including self-harm. However, current studies have produced contradictory findings with limited trend data.Aims Nine years of linked individual-level administrative data were utilised to examine changes in hospital-presenting self-harm and ideation (thoughts of self-harm or suicide)
-
Long-Term Use of Benzodiazepines and Benzodiazepine-Related Drugs: A Register-Based Danish Cohort Study on Determinants and Risk of Dose Escalation Am. J. Psychiatry (IF 17.7) Pub Date : 2023-09-20 Thomas Wolff Rosenqvist, Marie Kim Wium-Andersen, Ida Kim Wium-Andersen, Martin Balslev Jørgensen, Merete Osler
Objective: The authors investigated the frequency and determinants of long-term use and risk of dose escalation of benzodiazepines and benzodiazepine-related drugs (benzodiazepine receptor agonists, or BZRAs). Methods: All adults ages 20–80 years living in Denmark on January 1, 2000 (N=4,297,045) were followed for redeemed prescriptions of BZRAs in the Danish National Prescription Registry from January
-
Recent Secular Trends of Body Mass Index in Individuals With Bipolar Disorders and in the General Population Am. J. Psychiatry (IF 17.7) Pub Date : 2023-09-20 Hemen Najar, Erik Joas, Viktor Jonsson, Erik Pålsson, Mikael Landén
Objective: The aims of this study were to investigate secular trends and distribution of body mass index (BMI) among individuals with bipolar disorders and the general population between 2008 and 2019. Methods: Data were from the Swedish National Quality Register for Bipolar Disorder, where 24,423 adults with bipolar disorders were identified, and from the national Swedish Living Conditions Surveys
-
-
Fidelity and adaptation: reflections on recovery colleges globally Lancet Psychiatry (IF 64.3) Pub Date : 2023-09-19 Sophie Soklaridis, Holly Harris, Sam Gruszecki, Gail Bellissimo, Rowen Shier, Anna Di Giandomenico, Jordana Rovet, Georgia Black, Elizabeth Lin
Abstract not available
-
Violence risk assessment in forensic mental health Lancet Psychiatry (IF 64.3) Pub Date : 2023-09-20 Stephanie R Penney, Roland M Jones
Abstract not available
-
WHO Model Lists of Essential Medicines: methylphenidate for ADHD in children and adolescents Lancet Psychiatry (IF 64.3) Pub Date : 2023-09-20 Samuele Cortese, David Coghill, Gregory W Mattingly, Luis A Rohde, Ian C K Wong, Steven V Faraone
Abstract not available
-
The use of a national identification system to prevent misuse of benzodiazepines and Z-drugs in Japan Lancet Psychiatry (IF 64.3) Pub Date : 2023-09-20 Shotaro Kinoshita, Taishiro Kishimoto
Abstract not available
-
Milton Wainberg: co-creating scalable, equitable, and sustainable quality mental health care Lancet Psychiatry (IF 64.3) Pub Date : 2023-09-20 Udani Samarasekera
Abstract not available
-
Associations between post-traumatic stress disorders and psychotic symptom severity in adult survivors of developmental trauma: a multisite cross-sectional study in the UK and South Korea Lancet Psychiatry (IF 64.3) Pub Date : 2023-09-20 Ava J C Mason, Paul Jung, Seoyoung Kim, Hyejin Sim, Talya Greene, Neil Burgess, Chris R Brewin, James Bisby, Euitae Kim, Michael Bloomfield
Background Childhood maltreatment is a risk factor for the development of post-traumatic stress disorders and psychosis. However, the association between post-traumatic stress disorder (PTSD), including complex PTSD, and psychotic symptoms is unknown. We investigated whether the presence of PTSD and complex PTSD was associated with psychotic symptom severity within survivors of developmental trauma
-
Organisational and student characteristics, fidelity, funding models, and unit costs of recovery colleges in 28 countries: a cross-sectional survey Lancet Psychiatry (IF 64.3) Pub Date : 2023-09-19 Daniel Hayes, Holly Hunter-Brown, Elizabeth Camacho, Merly McPhilbin, Rachel A Elliott, Amy Ronaldson, Ioannis Bakolis, Julie Repper, Sara Meddings, Vicky Stergiopoulos, Lisa Brophy, Yuki Miyamoto, Stynke Castelein, Trude Gøril Klevan, Dan Elton, Jason Grant-Rowles, Yasuhiro Kotera, Claire Henderson, Mike Slade, , Tesnime Jebara
Background Recovery colleges were developed in England to support the recovery of individuals who have mental health symptoms or mental illness. They have been founded in many countries but there has been little international research on recovery colleges and no studies investigating their staffing, fidelity, or costs. We aimed to characterise recovery colleges internationally, to understand organisational
-
Violence risk assessment instruments in forensic psychiatric populations: a systematic review and meta-analysis Lancet Psychiatry (IF 64.3) Pub Date : 2023-09-20 Maya G T Ogonah, Aida Seyedsalehi, Daniel Whiting, Seena Fazel
Background Although structured tools have been widely used to predict violence risk in specialist mental health settings, there is uncertainty about the extent and quality of evidence of their predictive performance. We aimed to systematically review the predictive performance of tools used to assess violence risk in forensic mental health, where they are routinely administered. Methods In our systematic
-
Amphiregulin normalizes altered circuit connectivity for social dominance of the CRTC3 knockout mouse Mol. Psychiatry (IF 11.0) Pub Date : 2023-09-20 Ji-Seon Park, Hwon Heo, Min-Seok Kim, Seung-Eun Lee, Sukyoung Park, Ki-Hyun Kim, Young-Ho Kang, Je Seong Kim, Young Hoon Sung, Woo Hyun Shim, Dong-Hou Kim, Youngsup Song, Seung-Yong Yoon
-
CaMKK2 as an emerging treatment target for bipolar disorder Mol. Psychiatry (IF 11.0) Pub Date : 2023-09-20 Jacqueline Kaiser, Kevin Nay, Christopher R. Horne, Luke M. McAloon, Oliver K. Fuller, Abbey G. Muller, Douglas G. Whyte, Anthony R. Means, Ken Walder, Michael Berk, Anthony J. Hannan, James M. Murphy, Mark A. Febbraio, Andrew L. Gundlach, John W. Scott
-
Brain microvascular endothelial cells and blood-brain barrier dysfunction in psychotic disorders Mol. Psychiatry (IF 11.0) Pub Date : 2023-09-20 Paulo Lizano, Sovannarath Pong, Stephanie Santarriaga, Deepthi Bannai, Rakesh Karmacharya
-
Effects of deep brain stimulation on cognitive functioning in treatment-resistant depression: a systematic review and meta-analysis Mol. Psychiatry (IF 11.0) Pub Date : 2023-09-20 N. Runia, G. J. J. Mol, T. Hillenius, Z. Hassanzadeh, D. A. J. P. Denys, I. O. Bergfeld
-
Perceptual learning deficits mediated by somatostatin releasing inhibitory interneurons of olfactory bulb in an early life stress mouse model Mol. Psychiatry (IF 11.0) Pub Date : 2023-09-19 Meenakshi Pardasani, Anantha Maharasi Ramakrishnan, Sarang Mahajan, Meher Kantroo, Eleanor McGowan, Susobhan Das, Priyadharshini Srikanth, Sanyukta Pandey, Nixon M. Abraham
-
Functional genomic mechanisms of opioid action and opioid use disorder: a systematic review of animal models and human studies Mol. Psychiatry (IF 11.0) Pub Date : 2023-09-15 Camille Falconnier, Alba Caparros-Roissard, Charles Decraene, Pierre-Eric Lutz
-
Mitochondrial health index correlates with plasma circulating cell-free mitochondrial DNA in bipolar disorder Mol. Psychiatry (IF 11.0) Pub Date : 2023-09-15 Rafaela C. Cordeiro, Camila N. C. Lima, Gabriel R. Fries, Giovana Zunta-Soares, Jair C. Soares, João Quevedo, Giselli Scaini
-
Environment and White Matter: Risk and Resilience Factors Biol. Psychiatry (IF 10.6) Pub Date : 2023-09-15 Sara Poletti, Matteo Carminati, Raffaella Zanardi
Abstract not available
-
Understanding depression beyond the “mind-body” dichotomy World Psychiatry (IF 73.3) Pub Date : 2023-09-15 Mario Maj
In both the ICD-11 and the DSM-5, the core symptoms of depression are reported to be depressed mood (e.g., feeling sad, down or hopeless) and markedly diminished interest or pleasure in activities. However, in the ICD-10 diagnostic guidelines, a third core symptom was also identified: “fatigue or low energy”. In two regions of the world (Latin America and East Asia), “fatigue” is the most commonly
-
The challenges of defining and managing treatment-resistant depression in research and practice World Psychiatry (IF 73.3) Pub Date : 2023-09-15 Maurizio Fava
McIntyre et al1, in their excellent paper appearing in this issue of the journal, successfully tackle a critical issue in the field of depression: how should we define treatment-resistant depression (TRD) and how can we best manage it? They point out that a consensus definition of TRD with demonstrated predictive utility in terms of clinical decision-making and health outcomes does not currently exist
-
The lived experience of depression: a bottom-up review co-written by experts by experience and academics World Psychiatry (IF 73.3) Pub Date : 2023-09-15 Paolo Fusar-Poli, Andrés Estradé, Giovanni Stanghellini, Cecilia Maria Esposito, René Rosfort, Milena Mancini, Peter Norman, Julieann Cullen, Miracle Adesina, Gema Benavides Jimenez, Caroline da Cunha Lewin, Esenam A. Drah, Marc Julien, Muskan Lamba, Edwin M. Mutura, Benny Prawira, Agus Sugianto, Jaleta Teressa, Lawrence A. White, Stefano Damiani, Candida Vasconcelos, Ilaria Bonoldi, Pierluigi Politi
We provide here the first bottom-up review of the lived experience of depression, co-written by experts by experience and academics. First-person accounts within and outside the medical field were screened and discussed in collaborative workshops involving numerous individuals with lived experience of depression, family members and carers, representing a global network of organizations. The material
-
Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management World Psychiatry (IF 73.3) Pub Date : 2023-09-15 Michael Berk, Ole Köhler-Forsberg, Megan Turner, Brenda W.J.H. Penninx, Anna Wrobel, Joseph Firth, Amy Loughman, Nicola J. Reavley, John J. McGrath, Natalie C. Momen, Oleguer Plana-Ripoll, Adrienne O'Neil, Dan Siskind, Lana J. Williams, Andre F. Carvalho, Lianne Schmaal, Adam J. Walker, Olivia Dean, Ken Walder, Lesley Berk, Seetal Dodd, Alison R. Yung, Wolfgang Marx
Populations with common physical diseases – such as cardiovascular diseases, cancer and neurodegenerative disorders – experience substantially higher rates of major depressive disorder (MDD) than the general population. On the other hand, people living with MDD have a greater risk for many physical diseases. This high level of comorbidity is associated with worse outcomes, reduced adherence to treatment
-
Community care for people with mental illness: challenges emerging in the 2020s and consequent recommendations World Psychiatry (IF 73.3) Pub Date : 2023-09-15 Norman Sartorius
The later years of the 20th and the beginning of the 21st century – coinciding with deinstitutionalization and shift to managing mental health problems outside of hospitals – have been characterized by several socioeconomic trends which are of major importance for the strategies of community mental health care1, 2. The rampant urbanization is one of these trends. All the predictions are in agreement
-
Family psychoeducation in the early stages of mood and psychotic disorders World Psychiatry (IF 73.3) Pub Date : 2023-09-15 David J. Miklowitz
When combined with pharmacotherapy, family psychoeducation and skills training are key strategies for preventing, delaying or minimizing the severity of illness episodes in major psychiatric disorders1-3. High levels of expressed emotion – as indicated by critical comments, hostility and/or emotional overinvolvement from caregivers – are associated with high rates of recurrence in patients with schizophrenia
-
Putting psychological interventions first in primary health care World Psychiatry (IF 73.3) Pub Date : 2023-09-15 Mark van Ommeren, Sian Lewis, Edith van't Hof, Kenneth Carswell
Task-sharing – in which specialists train, supervise and support non-specialist health care providers – is proven to be acceptable, feasible and effective in scaling up mental health care for depressive and anxiety disorders1. In this perspective, we focus on reasons for and barriers to task-sharing of psychological interventions in primary health care. We also cover what the World Health Organization
-
Challenges in improving mental health literacy at population level World Psychiatry (IF 73.3) Pub Date : 2023-09-15 Claire Henderson
The expression “mental health literacy” was introduced in 1997 by Jorm et al1, referring to “knowledge and beliefs about mental disorders which aid their recognition, management or prevention”. Compared to contemporaneous programmes aiming to reduce stigma and discrimination related to mental illness, this construct reflected a broader and positively framed public mental health goal. However, the concept
-
Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions World Psychiatry (IF 73.3) Pub Date : 2023-09-15 Roger S. McIntyre, Mohammad Alsuwaidan, Bernhard T. Baune, Michael Berk, Koen Demyttenaere, Joseph F. Goldberg, Philip Gorwood, Roger Ho, Siegfried Kasper, Sidney H. Kennedy, Josefina Ly-Uson, Rodrigo B. Mansur, R. Hamish McAllister-Williams, James W. Murrough, Charles B. Nemeroff, Andrew A. Nierenberg, Joshua D. Rosenblat, Gerard Sanacora, Alan F. Schatzberg, Richard Shelton, Stephen M. Stahl, Madhukar
Treatment-resistant depression (TRD) is common and associated with multiple serious public health implications. A consensus definition of TRD with demonstrated predictive utility in terms of clinical decision-making and health outcomes does not currently exist. Instead, a plethora of definitions have been proposed, which vary significantly in their conceptual framework. The absence of a consensus definition
-
Recent developments pertaining to treatment-resistant depression: a 40-year perspective World Psychiatry (IF 73.3) Pub Date : 2023-09-15 Michael E. Thase
With the increasing recognition that major depressive disorder (MDD) is one of the world greatest public health problems1, 2, there have recently been concerted efforts to ensure that people suffering from this condition are promptly recognized, accurately diagnosed, and vigorously treated. Indeed, a relatively wide range of proven treatments are now available to help depressed people, and health care
-
Treatment-resistant depression invites persistent reflection World Psychiatry (IF 73.3) Pub Date : 2023-09-15 Gordon Parker
As admirably detailed by McIntyre et al1, most definitions of treatment-resistant depression (TRD) weight failure to respond to a set of antidepressant medications and other physical treatment options. Is this the optimal paradigm when major depressive episodes may be caused not only by biological factors, but also by social and psychological ones? Wouldn't we expect, for example, that a woman depressed
-
Challenges of research on treatment-resistant depression: a clinician's perspective World Psychiatry (IF 73.3) Pub Date : 2023-09-15 A. John Rush
I think we should be grateful to McIntyre et al1 for their extraordinarily thorough and balanced review of treatment-resistant depression (TRD). They note that this condition poses a plethora of clinical research challenges. Here I offer a few suggestions that might make research more cost-efficient and clinically generalizable. First, we should develop tools to systematically identify treatable causes
-
Does treatment-resistant depression need psychotherapy? World Psychiatry (IF 73.3) Pub Date : 2023-09-15 Myrna M. Weissman
Congratulations are well deserved for this review by 27 psychiatric leaders, representing 14 countries, including 294 references1. This highly researched, well-written paper describes the characteristics of treatment-resistant depression (TRD), including prevalence, risks, clinical features, costs, public health burden, management and treatments. Despite the wealth of information provided, lingering
-
From treatment resistance to sequential treatments of depression World Psychiatry (IF 73.3) Pub Date : 2023-09-15 Pim Cuijpers
McIntyre et al1 provide an excellent overview of “treatment-resistant depression” (TRD) and of the ways future research can contribute to a better knowledge on how to handle the many patients with depression who do not respond to treatment. However, I argue here that the notion of TRD is based on a misconception of the effects of treatments in depression, and that it is much better to focus research
-
Complexities of treatment-resistant depression: cautionary notes and promising avenues World Psychiatry (IF 73.3) Pub Date : 2023-09-15 Toshi A. Furukawa
Depressive episodes can be of mild intensity and transient, but – especially in tertiary care settings – they are often chronic and/or relapsing. As clinicians we often see people towards the latter end of this spectrum, including “treatment-resistant depression” (TRD), and spend much of our efforts in treating them. McIntyre et al1 competently and comprehensively review the TRD definition, prevalence
-
The psychedelic experience and treatment-resistant depression World Psychiatry (IF 73.3) Pub Date : 2023-09-15 Guy M. Goodwin
Interest in the use of serotonergic agonists such as psilocybin in treatment-resistant depression (TRD) has grown more quickly than the evidence on which to base a final opinion, as emphasized by McIntyre et al1 in their review. Psilocybin, once metabolized to psilocin, activates 5-HT2A receptors, enhancing GABA function in local circuits in the cortex and increasing connectivity between functional
-
Treatment-resistant depression: where to find hope? World Psychiatry (IF 73.3) Pub Date : 2023-09-15 Daniel Souery
McIntyre et al's paper1 is not just another literature review on the topic of treatment-resistant depression (TRD). It puts everyone in agreement and offers a concrete basis for a constructive reflection on the subject. More than that, it invites us to approach TRD in all its facets, the most complex but also those still unsuspected. Since the 1970s, the scientific literature on TRD has abounded with